Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
Aditya Bardia, Kathleen Harnden, Lauren Mauro, Angela Pennisi, Melissa Armitage, Hatem Soliman, Aditya Bardia, Kathleen Harnden, Lauren Mauro, Angela Pennisi, Melissa Armitage, Hatem Soliman
Abstract
The treatment of metastatic breast cancer (mBC) has evolved significantly in the past several years with the approval of new targeted agents. Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate with a topoisomerase I inhibitor payload, is a new addition to the class of therapies that target the human epidermal growth factor 2 (HER2) receptor. T-DXd was approved in the US in December 2019 for patients with HER2-positive metastatic or unresectable breast cancer who have received 2 or more prior anti-HER2-based regimens in the metastatic setting. In the DESTINY-Breast01 phase II trial (NCT03248492), T-DXd demonstrated high rates of durable responses in heavily pretreated patients with HER2-positive mBC, with a confirmed objective response rate of 62%, median duration of response of 18.2 months, and median progression-free survival of 19.4 months. In addition to efficacy, successful implementation of any new anticancer therapy includes learning how to prevent, monitor, and manage treatment-related adverse events. As T-DXd becomes more widely used, information can be gained from real-world clinical practices, institutional approaches, and the collaboration of multidisciplinary oncology teams who treat patients with T-DXd. This article reviews practical insights and management of nausea and vomiting, neutropenia, interstitial lung disease, risk of cardiotoxicity, and other adverse events associated with T-DXd administration from the perspective of health care providers who have experience utilizing T-DXd.
Keywords: breast neoplasm; clinical practice patterns; drug-related side effects and adverse reactions; trastuzumab deruxtecan.
© The Author(s) 2022. Published by Oxford University Press.
Figures
References
- American Cancer Society. Targeted drug therapy for breast cancer. Available at . Updated May 31, 2019. Accessed July 26, 2019.
- Howlader N, Altekruse SF, Li CI, et al. . US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.
- Wolff AC, Hammond ME, Hicks DG, et al. . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256. 10.5858/arpa.2013-0953-SA.
- Winstanley J, Cooke T, Murray GD, et al. . The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991;63(3):447-450.
- Seah DS, Luis IV, Macrae E, et al. . Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014;12(1):71-80.
- Nakada T, Sugihara K, Jikoh T, et al. . The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185.
- Enhertu®(fam-trastuzumab deruxtecan-nxki) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; Wilmington, DE: Astrazeneca pharmaceuticals LP; 2021.
- Ogitani Y, Hagihara K, Oitate M, et al. . Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039-1046.
- Modi S, Saura C, Yamashita T, et al. . Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621.
- Enhertu® approved in Japan for the treatment of patients with HER2 positive metastatic gastric cancer. Available at . Accessed July 16, 2021.
- Saura C, Modi S, Krop I, et al. . Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer: updated survival results from a phase 2 trial (DESTINY-Breast01). Presented at: The European Society for Medical Oncology annual meeting; September 16-21, 2021.
- Cortés J, Kim SB, Chung WP, et al. . Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143-1154.
- Herceptin® (trastuzumab) [Prescribing Information]. South San Francisco, CA: Genentech, Inc; 2021.
- Kadcyla® (ado-trastuzumab emtansine) [Prescribing Information]. South San Francisco, CA: Genentech, inc; 2020.
- Perjeta® (pertuzumab) [Prescribing Information]. South San Francisco, CA: Genentech, Inc; 2019.
- Margenza® (margetuximab-cmkb) [Prescribing Information]. Rockville, MD: Macrogenics, inc; 2020.
- Modi S, Saura C, Yamashita Tet al. . Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer. Presented at: San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020.
- NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines®) for Antiemesis v.1.2021. © National Comprehensive Cancer Network, Inc.2021. Available at . Accessed May 19, 2021.
- Stankowicz M, Mauro L, Harnden K, et al. . Management of chemotherapy-induced nausea and vomiting with trastuzumab deruxtecan: a case series. Breast Care. 2021;16(4):408-411. 10.1159/000511049.
- Neupogen® (filgrastim) [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc; 1991.
- Neulasta® (pegfilgrastim) [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc; 2002.
- Daiichi Sankyo. Data on file. 2022.
- Kubo K, Azuma A, Kanazawa M, et al. . Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260-277.
- Raghu G, Remy-Jardin M, Myers J, et al. . The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory. Am J Respir Crit Care Med. 2019;200(9):1089-1092.
- Kostakou PM, Kouris NT, Kostopoulos VS, et al. . Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2019;24(1):91-100.
- Berger AM, Abernethy AP, Atkinson A, et al. . NCCN clinical practice guidelines: cancer-related fatigue. J Natl Compr Canc Netw. 2010;8(8):904-931.
Source: PubMed